Drug intelligence / Profile preview

botulinum toxin

Development stage
Approved
Lead developer
AbbVie
Modality
Recombinant Proteins and Enzymes
Administration
Intradermal, Intramuscular
01

Overview

Botulinum toxin is a potent neurotoxic protein produced by the bacterium *Clostridium botulinum* and related species. It acts as a zinc-dependent endopeptidase that specifically cleaves SNARE proteins (such as SNAP-25 or synaptobrevin) within peripheral cholinergic nerve terminals. This cleavage prevents the fusion of acetylcholine-containing vesicles with the presynaptic membrane, thereby inhibiting the release of acetylcholine and causing temporary muscle paralysis or inhibition of sweat gland activity. In clinical practice, various formulations (e.g., onabotulinumtoxinA, abobotulinumtoxinA) are used for a wide range of indications, including muscle spasticity, cervical dystonia, chronic migraine, and hyperhidrosis. In the context of localized epidermolysis bullosa simplex (LEBS), botulinum toxin injections are evaluated for their ability to reduce sweating (hyperhidrosis), which is a major trigger for friction-induced blistering in these patients.

Brand names
DysportBotoxXeominJeuveauMyoblocDaxxify
Other names
botulinic toxinbotulinum neurotoxinBoNTbotulinum toxin type Abotulinum toxin type B
02

Targets

SNAP25 (Synaptosome-associated protein 25)VAMP2 (Vesicle-associated membrane protein 2)

Beyond the preview

Go deeper on botulinum toxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call